Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2026-01-01 @ 8:57 AM
Study NCT ID:
NCT00550459
Status:
COMPLETED
Last Update Posted:
2011-04-28
First Post:
2007-10-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007010', 'term': 'Hyponatremia'}], 'ancestors': [{'id': 'D014883', 'term': 'Water-Electrolyte Imbalance'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077602', 'term': 'Tolvaptan'}], 'ancestors': [{'id': 'D001552', 'term': 'Benzazepines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'frank.czerwiec@otsuka.com', 'phone': '(240) 683-3523', 'title': 'Frank Czerwiec, MD, PhD; Sr. Director, Global Clinical Development', 'organization': 'Otsuka Pharmaceutical Development & Commercialization, Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}, 'limitationsAndCaveats': {'description': 'Pilot study powered only for serum Na+ improvements. Trial lacked sufficient power to detect changes in neurocognitive test scores and SF-12 and HDS outcomes.'}}, 'adverseEventsModule': {'timeFrame': '28 Days', 'description': 'collection/elicitation of adverse event incidence', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days', 'otherNumAtRisk': 28, 'otherNumAffected': 13, 'seriousNumAtRisk': 28, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days', 'otherNumAtRisk': 29, 'otherNumAffected': 17, 'seriousNumAtRisk': 29, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Dermatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 4, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Dry Mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 4, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 3, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Pollakiuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Thirst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 6, 'numAffected': 6}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Urine output increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}], 'seriousEvents': [{'term': 'Abdominal adhesions', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Bradycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Chronic obstructive pulmonary disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Large intestinal obstruction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 28, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 29, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (10.0)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0.20', 'spread': '0.61', 'groupId': 'OG000'}, {'value': '0.39', 'spread': '0.49', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.08', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.23', 'ciLowerLimit': '-0.03', 'ciUpperLimit': '0.50', 'pValueComment': 'Secondary endpoints were ordered in 5 tiers to be analyzed only when \\>=1 of the endpoints in the prior tier were significant. Since primary endpoint not stat significant, analyses of secondary endpoint tiers presented for exploratory purposes only', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.55', 'groupDescription': 'Analysis of covariance (ANCOVA) with factors of treatment,disease severity (\\<130mEq/L \\[mmol/L\\] or ≥130mEq/L \\[mmol/L\\] at baseline),age (\\<65, ≥65 to \\<75,and ≥75 years) (factor with 6 Degrees of Freedom), and covariate baseline used to fit primary endpoint using the intent-to-treat (ITT) dataset. Estimated treatment effect and its 95% confidence interval (CI) provided under the model with p-value. A 2-sided alpha (0.05) applied to the primary analysis. Primary analysis based on observed cases (OC).', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'statisticalComment': 'ANCOVA with factors of treatment, disease severity, age(6 Degrees of Freedom), and covariate baseline to fit primary endpoint using the ITT dataset.', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize "yes" 50 times;Choice=recognize "yes" or "no" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \\& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data', 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Analysis based upon observed cases (OC).'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0.21', 'spread': '0.86', 'groupId': 'OG000'}, {'value': '0.33', 'spread': '0.41', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.21', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.20', 'ciLowerLimit': '-0.12', 'ciUpperLimit': '0.51', 'pValueComment': 'ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.63', 'groupDescription': 'Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population', 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population with OC'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0.04', 'spread': '0.36', 'groupId': 'OG000'}, {'value': '0.31', 'spread': '0.46', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.02', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.27', 'ciLowerLimit': '0.04', 'ciUpperLimit': '0.51', 'pValueComment': 'ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.41', 'groupDescription': 'Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population', 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population with OC'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0.24', 'spread': '0.75', 'groupId': 'OG000'}, {'value': '0.48', 'spread': '0.91', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.21', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.26', 'ciLowerLimit': '-0.15', 'ciUpperLimit': '0.67', 'pValueComment': 'ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.83', 'groupDescription': 'Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population', 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population with OC'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Overall Neurocognitive Composite Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0.19', 'spread': '0.39', 'groupId': 'OG000'}, {'value': '0.30', 'spread': '0.39', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.16', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.12', 'ciLowerLimit': '-0.05', 'ciUpperLimit': '0.30', 'pValueComment': 'ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '0.39', 'groupDescription': 'Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 22', 'description': 'Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population', 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population with OC'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1.06', 'spread': '5.63', 'groupId': 'OG000'}, {'value': '-0.43', 'spread': '1.54', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.23', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.51', 'ciLowerLimit': '-4.02', 'ciUpperLimit': '1.00', 'pValueComment': 'ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '3.53', 'groupDescription': 'Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population', 'unitOfMeasure': 'Seconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population with OC'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Postural Stability Test', 'denoms': [{'units': 'Participants', 'counts': [{'value': '25', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1.3', 'spread': '4.68', 'groupId': 'OG000'}, {'value': '-0.35', 'spread': '2.33', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '0.18', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.83', 'ciLowerLimit': '-2.04', 'ciUpperLimit': '0.38', 'pValueComment': 'ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '3.51', 'groupDescription': 'Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population', 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population with LOCF (this group includes missing values)'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Serum Sodium; ITT Population', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '2.23', 'spread': '3.51', 'groupId': 'OG000'}, {'value': '7.04', 'spread': '3.39', 'groupId': 'OG001'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.75', 'ciLowerLimit': '2.89', 'ciUpperLimit': '6.60', 'pValueComment': 'ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.', 'dispersionType': 'STANDARD_DEVIATION', 'dispersionValue': '3.45', 'groupDescription': 'Per-protocol, secondary endpoints were ordered in 5 tiers and were to be analyzed only when at least 1 of the endpoints in the previous tier was significant. As the primary endpoint was not statistically significant, the analyses of subsequent secondary endpoint tiers are presented for exploratory purposes only.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': 'Baseline and Day 22', 'description': 'Change from Baseline to Day 22 in Serum Sodium; ITT population', 'unitOfMeasure': 'mEq/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'ITT population with OC'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Vital Sign Abnormalities: Blood Pressure', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of abnormal systolic \\& diastolic blood pressure values post-baseline (abnormal systolic values: \\>=180 mmHg + increase of \\>=20 mmHg, \\<= 90 mmHg + decrease \\>=20 mmHg; abnormal diastolic values: \\>=105 mmHg+increase of \\>=15 mmHg, \\<=50 mmHg + decrease of \\>= 15 mmHg)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Vital Sign Abnormalities: Pulse Rate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of abnormal pulse rate post-baseline \\[abnormal values: \\>=120 beats per minute (bpm) + increase of \\>=15 bpm; \\<=50 bpm + decrease of \\>=15 bpm\\]', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Vital Sign Abnormalities: Body Weight', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \\>=7%)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Vital Sign Abnormalities: Body Temperature', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \\>=1.1 to \\>=38.3 degrees Celsius)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '27', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Hematology Laboratory Abnormalities: Neutrophils', 'denoms': [{'units': 'Participants', 'counts': [{'value': '26', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QT\\>500 msec) post-baseline', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \\> 100 msec)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: ST Segment', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: T wave', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}, {'type': 'SECONDARY', 'title': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '29', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'OG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: arrhythmia', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety population defined as all randomized subjects who consumed at least 1 dose of trial medication'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'FG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '28'}, {'groupId': 'FG001', 'numSubjects': '29'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '27'}, {'groupId': 'FG001', 'numSubjects': '26'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '3'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}], 'recruitmentDetails': "16 United States (US) sites/clinics; first subject signed informed consent on 9/11/07; last subject's final visit on 12/16/08"}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '57', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'Placebo tablet given once daily for 21 days'}, {'id': 'BG001', 'title': 'Tolvaptan (15-60 mg)', 'description': 'Tolvaptan tablet 15-60 mg given once daily for 21 days'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '22', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '45', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age Continuous', 'classes': [{'categories': [{'measurements': [{'value': '71.3', 'spread': '9.7', 'groupId': 'BG000'}, {'value': '71.1', 'spread': '10.2', 'groupId': 'BG001'}, {'value': '71.2', 'spread': '9.9', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '19', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '34', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '14', 'groupId': 'BG001'}, {'value': '23', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '57', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 57}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-04', 'dispFirstSubmitDate': '2010-02-24', 'completionDateStruct': {'date': '2009-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2011-04-26', 'studyFirstSubmitDate': '2007-10-25', 'dispFirstSubmitQcDate': '2010-02-24', 'resultsFirstSubmitDate': '2010-08-05', 'studyFirstSubmitQcDate': '2007-10-26', 'dispFirstPostDateStruct': {'date': '2010-03-04', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2011-04-28', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2011-04-26', 'studyFirstPostDateStruct': {'date': '2007-10-29', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2011-04-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize "yes" 50 times;Choice=recognize "yes" or "no" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \\& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population'}, {'measure': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population'}, {'measure': 'Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population'}, {'measure': 'Change From Baseline in Overall Neurocognitive Composite Score', 'timeFrame': 'baseline and Day 22', 'description': 'Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population'}, {'measure': 'Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population'}, {'measure': 'Change From Baseline in Postural Stability Test', 'timeFrame': 'baseline and Day 22', 'description': 'Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population'}, {'measure': 'Change From Baseline in Serum Sodium; ITT Population', 'timeFrame': 'Baseline and Day 22', 'description': 'Change from Baseline to Day 22 in Serum Sodium; ITT population'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Blood Pressure', 'timeFrame': '28 days', 'description': 'Incidence of abnormal systolic \\& diastolic blood pressure values post-baseline (abnormal systolic values: \\>=180 mmHg + increase of \\>=20 mmHg, \\<= 90 mmHg + decrease \\>=20 mmHg; abnormal diastolic values: \\>=105 mmHg+increase of \\>=15 mmHg, \\<=50 mmHg + decrease of \\>= 15 mmHg)'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Pulse Rate', 'timeFrame': '28 days', 'description': 'Incidence of abnormal pulse rate post-baseline \\[abnormal values: \\>=120 beats per minute (bpm) + increase of \\>=15 bpm; \\<=50 bpm + decrease of \\>=15 bpm\\]'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Body Weight', 'timeFrame': '28 days', 'description': 'Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \\>=7%)'}, {'measure': 'Number of Patients With Vital Sign Abnormalities: Body Temperature', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \\>=1.1 to \\>=38.3 degrees Celsius)'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin', 'timeFrame': '28 days', 'description': 'Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)'}, {'measure': 'Number of Patients With Hematology Laboratory Abnormalities: Neutrophils', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)'}, {'measure': 'Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QT\\>500 msec) post-baseline'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \\> 100 msec)'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: ST Segment'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: T wave'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)'}, {'measure': 'Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia', 'timeFrame': '28 days', 'description': 'Incidence of potentially clinically significant ECG abnormalities: arrhythmia'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Hyponatremia', 'Cognitive', 'Neurological Function', 'Elderly'], 'conditions': ['Hyponatremia']}, 'descriptionModule': {'briefSummary': 'Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.', 'detailedDescription': "Subjects will be randomized, with stratification by baseline sodium \\<130 or ≥ 130 mEq/L\\[mmol/L\\] to receive either tolvaptan 15 mg tablet or matching placebo tablet at doses of 15, 30 or 60 mg for 21 days. During this period, fluid restrictions should be loosened or suspended, until the subject's response to therapy can be evaluated, typically over the first few days of therapy. Fluid restriction may be reinstituted at any time in subjects whose sodium fails to improve or worsens with study therapy. A forced-titration up to 60 mg of study drug by day 3 to 7 will be based on the subject's serum sodium Subjects entering the study with a serum sodium concentration less than 130 mEq/L\\[mmol/L\\] may be fluid restricted if necessary at the discretion of the Investigator. Subjects should be monitored closely during the first 24 hours of treatment for dosing titration. The total dosing duration will be up to 21 days (plus 3 day treatment window). Subjects will return to the clinic on Day 22 (+3 days) for assessments and will complete a follow-up visit on Day 28 (+2 days)."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '50 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Women and men 50 years of age or older.\n* Serum Sodium ≥123 and ≤ 134 mEq/L \\[mmol/L\\]at screening and baseline.\n* Subjects with serum sodium concentrations ≥118 and ≤122 mEq/L\\[mmol/L\\] at screening and baseline may be entered into the trial based on consultation and approval from the study medical monitor.\n\nExclusion Criteria:\n\n* Conditions or history which may present a safety concern to the subject or their offspring or extreme susceptibility to hypotension with sudden fluid loss (aquaresis).\n* Hyponatremia that is acute, easily reversible, artifactual, or due to a condition not associated with vasopressin excess or likely to respond to aquaretic therapy.\n* Conditions associated with an independent imminent risk of morbidity and mortality.\n* Conditions which may confound the assessment of endpoints, history of poor compliance, participation in a clinical trial believed by the PI or Sponsor likely to confound endpoint assessments.\n* Conditions which may confound primary endpoints of cognitive function.'}, 'identificationModule': {'nctId': 'NCT00550459', 'acronym': 'INSIGHT', 'briefTitle': 'Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients', 'organization': {'class': 'INDUSTRY', 'fullName': 'Otsuka Pharmaceutical Development & Commercialization, Inc.'}, 'officialTitle': 'A Pilot, Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Effects of Titrated Oral Tolvaptan 15, 30, or 60 mg QD on Cognitive and Neurological Function in Elderly Hyponatremic Patients', 'orgStudyIdInfo': {'id': '156-04-246'}, 'secondaryIdInfos': [{'id': 'INSIGHT'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': '1', 'description': 'Placebo tablet given once a day for 21 days', 'interventionNames': ['Drug: Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': '2', 'description': 'Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.', 'interventionNames': ['Drug: Tolvaptan']}], 'interventions': [{'name': 'Tolvaptan', 'type': 'DRUG', 'otherNames': ['OPC-41061'], 'description': '15-60 mg oral tablet given once a day for 21 days.', 'armGroupLabels': ['2']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo tablet given once daily for 21 days', 'armGroupLabels': ['1']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90250', 'city': 'Hawthorne', 'state': 'California', 'country': 'United States', 'facility': 'Sarah. S. Olelewe, MD', 'geoPoint': {'lat': 33.9164, 'lon': -118.35257}}, {'zip': '92083', 'city': 'Vista', 'state': 'California', 'country': 'United States', 'facility': 'Progressive Clinical Research', 'geoPoint': {'lat': 33.20004, 'lon': -117.24254}}, {'zip': '80907', 'city': 'Colorado Springs', 'state': 'Colorado', 'country': 'United States', 'facility': 'Pikes Peak Cardiology', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'zip': '33770', 'city': 'Largo', 'state': 'Florida', 'country': 'United States', 'facility': 'Innovative Research of West FL', 'geoPoint': {'lat': 27.90979, 'lon': -82.78842}}, {'zip': '33950', 'city': 'Punta Gorda', 'state': 'Florida', 'country': 'United States', 'facility': 'Coastal Nephrology Assoc. Research Center', 'geoPoint': {'lat': 26.92978, 'lon': -82.04537}}, {'zip': '30094', 'city': 'Conyers', 'state': 'Georgia', 'country': 'United States', 'facility': 'Rockdale Medical Research Associates', 'geoPoint': {'lat': 33.66761, 'lon': -84.01769}}, {'zip': '71457', 'city': 'Natchitoches', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Otis Barnum, DO', 'geoPoint': {'lat': 31.76072, 'lon': -93.08627}}, {'zip': '58106', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Lillestol Research, LLC', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '29201', 'city': 'Columbia', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Carolina Research Associates', 'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}, {'zip': '37087', 'city': 'Lebanon', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Wayne O. Wells, MD', 'geoPoint': {'lat': 36.20811, 'lon': -86.2911}}, {'zip': '77043', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Memorial Clinical Associates', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '22908', 'city': 'Charlottesville', 'state': 'Virginia', 'country': 'United States', 'facility': 'Mitchell Rosner, MD', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}], 'overallOfficials': [{'name': 'Joseph Verbalis, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Georgetown University, Washington, DC, 20007 USA'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Otsuka Pharmaceutical Development & Commercialization, Inc.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Otsuka Pharmaceutical Co., Ltd.', 'class': 'INDUSTRY'}], 'responsibleParty': {'oldNameTitle': 'Dorothee Oberdhan, Manager, Global Clinical Development', 'oldOrganization': 'Otsuka Pharmaceutical Development & Commercialization, Inc.'}}}}